GLSI
Price
$16.98
Change
-$0.37 (-2.13%)
Updated
Oct 2 closing price
Capitalization
272.87M
45 days until earnings call
Intraday BUY SELL Signals
NVAX
Price
$10.46
Change
-$0.14 (-1.32%)
Updated
Oct 2 closing price
Capitalization
1.78B
34 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

GLSI vs NVAX

GLSI vs NVAX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
GLSI vs. NVAX commentary
Oct 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GLSI is a Hold and NVAX is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
GLSI vs NVAX: Fundamental Ratings
GLSI
NVAX
OUTLOOK RATING
1..100
9138
VALUATION
overvalued / fair valued / undervalued
1..100
84
Overvalued
75
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4138
P/E GROWTH RATING
1..100
10013
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NVAX's Valuation (75) in the Biotechnology industry is in the same range as GLSI (84) in the null industry. This means that NVAX’s stock grew similarly to GLSI’s over the last 12 months.

NVAX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as GLSI (100) in the null industry. This means that NVAX’s stock grew similarly to GLSI’s over the last 12 months.

NVAX's SMR Rating (100) in the Biotechnology industry is in the same range as GLSI (100) in the null industry. This means that NVAX’s stock grew similarly to GLSI’s over the last 12 months.

NVAX's Price Growth Rating (38) in the Biotechnology industry is in the same range as GLSI (41) in the null industry. This means that NVAX’s stock grew similarly to GLSI’s over the last 12 months.

NVAX's P/E Growth Rating (13) in the Biotechnology industry is significantly better than the same rating for GLSI (100) in the null industry. This means that NVAX’s stock grew significantly faster than GLSI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GLSINVAX
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
73%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 5 days ago
78%
Bullish Trend 4 days ago
79%
Declines
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
80%
COMPARISON
Comparison
Oct 03, 2026
Stock price -- (GLSI: $16.98 vs. NVAX: $10.46)
Brand notoriety: GLSI: Not notable vs. NVAX: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GLSI: 143% vs. NVAX: 79%
Market capitalization -- GLSI: $272.87M vs. NVAX: $1.78B
GLSI [@Biotechnology] is valued at $272.87M. NVAX’s [@Biotechnology] market capitalization is $1.78B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GLSI’s FA Score shows that 0 FA rating(s) are green while NVAX’s FA Score has 1 green FA rating(s).

  • GLSI’s FA Score: 0 green, 5 red.
  • NVAX’s FA Score: 1 green, 4 red.
According to our system of comparison, NVAX is a better buy in the long-term than GLSI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GLSI’s TA Score shows that 5 TA indicator(s) are bullish while NVAX’s TA Score has 5 bullish TA indicator(s).

  • GLSI’s TA Score: 5 bullish, 4 bearish.
  • NVAX’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, GLSI is a better buy in the short-term than NVAX.

Price Growth

GLSI (@Biotechnology) experienced а -6.81% price change this week, while NVAX (@Biotechnology) price change was -1.60% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.69%. For the same industry, the average monthly price growth was -14.41%, and the average quarterly price growth was -1.73%.

Reported Earning Dates

GLSI is expected to report earnings on Nov 16, 2026.

NVAX is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-3.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
GLSI
Daily Signal:
Gain/Loss:
NVAX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
URTY67.790.76
+1.13%
ProShares UltraPro Russell2000 (URTY)
OAKM29.530.17
+0.58%
Oakmark U.S. Large Cap ETF
PSCM94.260.09
+0.10%
Invesco S&P SmallCap Materials ETF (PSCM)
CCZ62.90N/A
N/A
Comcast Holdings Corp
GDXW37.32-0.54
-1.43%
Roundhill Gold Miners WeeklyPay ETF (GDXW)

GLSI and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLSI has been loosely correlated with RZLT. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if GLSI jumps, then RZLT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLSI
1D Price
Change %
GLSI100%
-3.88%
RZLT - GLSI
34%
Loosely correlated
-1.69%
IPSC - GLSI
33%
Loosely correlated
-5.85%
SPRY - GLSI
33%
Poorly correlated
-4.41%
MBIO - GLSI
32%
Poorly correlated
+0.97%
NVAX - GLSI
31%
Poorly correlated
-1.94%
More